SNY (Sanofi) 3-Year FCF Growth Rate : 10.80% (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi 3-Year FCF Growth Rate?

Sanofi's Free Cash Flow per Share for the six months ended in Jun. 2024 was $-0.20.

During the past 12 months, Sanofi's average Free Cash Flow per Share Growth Rate was -49.00% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 10.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 15.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Sanofi was 118.50% per year. The lowest was -15.10% per year. And the median was 3.90% per year.

Competitive Comparison of Sanofi's 3-Year FCF Growth Rate

For the Drug Manufacturers - General subindustry, Sanofi's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Sanofi's 3-Year FCF Growth Rate falls into.

Sanofi 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Sanofi (NAS:SNY) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Sanofi 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Sanofi's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.